.webp)
The market for cabazitaaxel is expected to reach USD 227.4 million by 2027, growing at a 5.3% CAGR over that time. The rapid increase in demand can be attributed to the demand levelling off after the epidemic is ended. The COVID-19 epidemic has been unprecedented and overwhelming, and demand for cabazitaxel has been lower than expected or more than expected in all countries. Cabazitaxel, a semi-synthetic derivative of a natural taxoid, is marketed under the trade name Jevtana. Taxane inhibits cellular mitosis and division while enhancing microtubule stability. It was developed by Sanofi-Aventis and approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer.
Following docetaxel-based therapy, capaztaxel is used in combination with prednisone to treat metastatic castration-resistant prostate cancer. It is used after surgically removing the testes when cancer has progressed to other body areas despite being treated to stop the production of testosterone.
COVID-19 Accelerated R&D Around Potential Benefits of Acetylcysteine
Prostate cancer incidence, technological advancements, and the prevalence of unmet medical needs are some of the key market drivers. Growing public knowledge of cancer and its treatments will fuel the market's expansion for cabazitaxel. Early stages of prostate cancer typically show no symptoms. The symptoms might be observed in the latter stages. Disruptions have a definite impact on the world cabazitaxel market. COVID-19 had a detrimental effect on a number of markets in 2020. Due to the epidemic, manufacturing businesses temporarily ceased operations, and elective surgeries were also suspended. The selling of cancer gadgets was also hampered by logistical issues and patients' reluctance to go to hospitals and clinics.
Business Research Insights Presents the Top 5 Cabazitaxel Manufacturing Companies Globally
1. Sanofi (France)
Sanofi S.A. is a French pharmaceutical and healthcare multinational with its headquarters in Paris. The company was first founded in 1973, then in 1999 it combined with Synthélabo to become Sanofi-Synthélabo. Sanofi-Synthélabo and Aventis, both the result of multiple prior mergers, united to form Sanofi-Aventis in 2004. In May 2011, it returned to using the name Sanofi. A part of the Euro Stoxx 50 stock market index is the firm.
Sanofi develops over-the-counter medicines in addition to doing research, developing, producing, and marketing pharmaceutical products, mostly for the prescription market. The company's seven main therapeutic areas include cardiovascular, central nervous system, diabetes, internal medicine, cancer, thrombosis, and vaccines, of which it is the world's largest manufacturer.
2. Tapi Teva (Israel)
Tapi Israeli global pharmaceutical business Teva Pharmaceutical Industries Ltd., better known as Teva Pharmaceuticals, is based in Tel Aviv. Generic medications are its main area of expertise, but it also has certain additional commercial interests in active pharmaceutical components and, to a lesser extent, patented drugs. When US-based Pfizer momentarily overtook Teva Pharmaceuticals as the biggest generic medicine producer, Teva Pharmaceuticals was still the market leader.
When Pfizer broke off its generic medication division through a deal with Mylan and created the new firm Viatris at the end of 2020, Teva reclaimed the top spot on the market. Teva ranks as the world's 18th-largest pharmaceutical firm overall. Israel, North America, Europe, Australia, and South America are among the countries where Teva has facilities. The Tel Aviv Stock Exchange lists Teva shares. The business belongs to the American Pharmaceutical Research and Manufacturers Association (PhRMA)
3. Fuan Pharmaceutical Group (China)
In the People's Republic of China, Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, conducts research and development, produces, and markets pharmaceutical intermediates, bulk medications, and formulations. It provides formulations such anti-infective, cardiovascular, digestive, leaflet, and other goods together with APIs and intermediates. In August 2013, the business changed its name from Chongqing Fuan Pharmaceutical (Group) Co., Ltd. to Fuan Pharmaceutical (Group) Co., Ltd. The People's Republic of China's Fuan Pharmaceutical (Group) Co., Ltd. was established in 2004 and has its headquarters there.
4. Fujian Yewpark Biological Co Ltd (China)
In order to create an industrial chain enterprise of Taxus Chinensis planting, extraction, and preparation production, the firm primarily engages in artificial culture, extraction, purification, semi-synthetic, and preparation production of Taxus Chinensis.
Our major products are anticancer Paclitaxel extraction and its auxiliary products, with an annual processing capacity of 6,000 tonnes of fresh yew leaves. Products made from high purity paclitaxel offer special anti-cancer capabilities. It is a successful and well-liked anti-cancer product.
5. Hetero Labs (India)
The largest manufacturer of anti-retroviral medications in the world is an Indian pharmaceutical business called Hetero. With a presence in 145+ countries and 30 years of expertise in the pharmaceutical industry, it is also one of the top makers of essential Active Pharmaceutical Ingredients (APIs) in the globe. APIs, generics, biosimilars, branded generics, and bespoke pharmaceutical services are all part of Hetero's business.
In 1993, Hetero Group made its modest debut as an API player in the Indian pharmaceutical industry. The company has developed over the past 20 years into one of the world's top producers of APIs as well as a pioneer in ARV APIs and FDFs. Hetero is currently one of India's top and biggest privately held pharmaceutical companies.
Growing Cancer Incidences to Fuel Market Growth
The main factor for the growth of the cabazitaxel market is the increase in heart disease and prostate cancer patients. The significant variables that will accelerate the market's growth rate are the introduction of novel prostate cancer medicines and the existence of pipeline drugs. The market's expansion will be positively influenced by other factors including technological innovations connected to screening and testing procedures and lifestyle changes.